Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, uniQure acquires global rights for the development and commercialization of APB-102, adding to its pipeline of gene therapies to treat neurological disorders.
Lead Product(s): APB-102
Therapeutic Area: Neurology Product Name: APB-102
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Uniqure
Deal Size: $55.0 million Upfront Cash: $10.0 million
Deal Type: Licensing Agreement January 31, 2023
Details:
The Phase 1/2 clinical trial is a multi-center, three-part study to evaluate the safety, tolerability, and efficacy of intrathecally administered APB-102 in patients with SOD1 ALS mutations.
Lead Product(s): APB-102
Therapeutic Area: Neurology Product Name: APB-102
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2021